TVRD
Tvardi Therapeutics, Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$33.49M
P/E Ratio
—
EPS
$-0.27
Beta
—
52W High
$43.65
52W Low
$2.75
50-Day MA
$3.43
200-Day MA
$10.57
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company at the forefront of developing innovative therapies for oncology and other significant medical issues. Leveraging its proprietary drug discovery platform, Tvardi specializes in small molecule therapies targeting protein degradation pathways, aiming to enhance treatment efficacy in cancer care. The company’s lead candidate, TVB-2640, disrupts cancer cell survival mechanisms, reflecting its commitment to advancing novel treatment options for patients with malignancies. With a robust pipeline and a focus on scientific excellence, Tvardi is strategically positioned to make a meaningful impact in the cancer therapeutics landscape.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-29.35M |
| Operating Margin | 0.00% |
| Return on Equity | -237.80% |
| Return on Assets | -68.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.55 |
| Price-to-Book | 2.30 |
| Price-to-Sales (TTM) | 559.61 |
| EV/Revenue | 539.62 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $9.38M |
| Float | $6.46M |
| % Insiders | 34.64% |
| % Institutions | 28.93% |
Historical Volatility
HV 10-Day
59.35%
HV 20-Day
85.99%
HV 30-Day
86.12%
HV 60-Day
74.12%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($8.17 target)
4
Buy3
Hold1
Strong SellMore HEALTHCARE Stocks
Data last updated: 5/25/2026